FuadEl RassiMD

Hematology • Atlanta, GA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias

Associate Professor, Hematology and Medical Oncology, Emory Univ Sch of Med

Join to view full profile

Dr. El Rassi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. El Rassi's full profile

Already have an account?

Office
80 Jesse Hill Jr Dr SE
Atlanta, GA 30303
Phone+1 404-616-3388

Summary

Dr. Fuad El Rassi is a hematologist based in Atlanta, GA, with subspecialties in hematologic oncology, myeloproliferative disorder hematology-oncology, and care for sickle cell and other anemias. He's an Associate Professor at Emory Medical Care Foundation and Emory University Hospital Midtown since 2014. Dr. El Rassi completed his fellowship in hematology and medical oncology at Emory University School of Medicine, and his residency in internal medicine at St Louis University School of Medicine, having graduated from American University of Beirut Faculty of Medicine. His clinical experience includes beta thalassemia, thrombocytopenia, acute myeloid leukemia, sickle-cell anemia, and lymphoma. He has several published works in distinguished medical journals and is actively involved in a number of clinical trials.

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 2008 - 2011
American University of Beirut Faculty of MedicineClass of 2006

Certifications & Licensure

GA State Medical License 2013 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases Start of enrollment: 2017 Apr 11
Completed
Phase 2
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Start of enrollment: 2016 Nov 01
Completed
Phase 2
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) Start of enrollment: 2017 Dec 22
Completed
Phase 2
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism Start of enrollment: 2019 Oct 16
Completed
Phase 2
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease Start of enrollment: 2019 Dec 10
Completed
Phase 2
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Start of enrollment: 2021 Mar 26
Recruiting
Phase 2, Phase 3
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease Start of enrollment: 2020 Jul 10
Completed
Phase 1
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) Start of enrollment: 2020 Feb 26
Recruiting
Phase 3
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease Start of enrollment: 2024 Jan 10
Recruiting
Phase 2
A Phase 2/3 Study in Adult and Pediatric Participants With SCD Start of enrollment: 2022 Sep 22
Recruiting
Phase 2, Phase 3
Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Start of enrollment: 2015 Jun 17
Completed
Phase 3
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Start of enrollment: 2013 May 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

34 citations
Relation Between Iron-Overload Indices, Cardiac Echo-Doppler, and Biochemical Markers in Thalassemia Intermedia
Hussain Isma'eel, Abdul Hamid El Chafic, Fuad El Rassi, Adlette Inati, Susan Koussa
The American Journal of Cardiology. 2008-08-01
3 citations
Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
Hirotomo Nakahara, Narayanaiah Cheedarla, Hans P Verkerke, Suneethamma Cheedarla, Shang-Chuen Wu
British Journal of Haematology. 2023-09-01
73 citations
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessme...
Ifeyinwa Osunkwo, Biree Andemariam, Caterina P. Minniti, Baba Inusa, Fuad El Rassi
American Journal of Hematology. 2021-04-01

Abstracts/Posters

Impact of Sickle Cell Disease Symptoms on PatientsÍ Daily Lives: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)
Fuad El-Rassi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Management Strategies and Satisfaction Levels in Patients with Sickle Cell Disease: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)
Fuad El-Rassi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Pria...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019